10 Best Mid Cap Stocks For 2014

Biotech in general has been one of the market�� hottest sectors this year thanks to plenty of mostly good news�along with�new IPOs while small cap biotech stocks Delcath Systems (NASDAQ: DCTH), ZIOPHARM Oncology Inc (NASDAQ: ZIOP), Recro Pharma (NASDAQ: REPH), TetraLogic Pharmaceuticals (NASDAQ: TLOG)�and TNI BioTech (OTCMKTS: TNIB) have also produced their share of news�this week or in recent weeks. Just consider the following:

Biotech Stock Bubble Debate in 14 Charts. Haven�� decided whether there is a bubble in the biotech sector just yet? The Street has a short but to the point article with 14 charts showing how biotech stocks have had an unbelievable�year, but have also underperformed the broader market in the past month with momentum-driven biotech stocks (mostly small caps or mid caps)�having been hit with some serious selling over the past month. There was�also a chart showing how well orphan drug stocks have performed���up until the past month. Charting Biotech Blowups. As noted by Business Insider, ISI analyst Mark Schoenebaum recently issued a note to clients that�included a chart counting the�number of biotech stock "blowups" each year since 1990 with a ��lowup��being defined as a�one day downward stock move of 25% or more. Apparently, Schoenebaum wrote: "If you look at the trend, it doesn't look scary to me . . . . what do you think?"

Top 10 Solar Companies To Watch In Right Now: Neogenomics Inc (NEO)

NeoGenomics, Inc. (NeoGenomics) operates a network of cancer-focused testing laboratories. The Company offers testing services, including Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) testing, this is the process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to antigens, and molecular testing, which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA), as well as the structure and function of genes at a molecular level.

The cancer testing services, that the Company offers to community-based pathologists are designed to be a natural extension of, and complementary to, the services that they perform within their own practices. In areas where the Company does not provide services to community-based pathology practices, it may directly serve oncology, dermatology, urology and other clinician practices that prefer to have a direct relationship with a laboratory for cancer-related genetic and molecular testing services. NeoGenomics services these types of clients with a global service offering where it performs both the technical and professional components of the tests ordered.

The Company offers tech-only flow cytometry and immunohistochemistry testing services. These types of testing services generally allow the professional interpretation component of a test to be billed separately from the technical component. Its NeoFISH, NeoFLOW and other tech-only service offerings allow properly trained and credentialed community-based pathologists to extend their own practices by performing ! professional interpretations services.

The Company's tech-only services are designed to give pathologists the option to choose, on a case by case basis, whether they want to order just the technical information and images relating to a specific test so they can perform the professional interpretation, or order global services and receive a test report, which includes a NeoGenomics Pathologist�� interpretation of the test results.

The Company also offers a set of global services to meet the needs of those clients who are not credentialed and trained in interpreting genetic tests and who are looking for specialists to interpret the testing results for them. In its global service offerings, its lab performs the technical component of the tests and its doctor of medicine (M.D.s) and doctor of philosophy (Ph.D) s to provide the interpretation services. Its genetic pathology solutions (GPS) report summarizes all relevant case data from its global services on one summary report.

The Company competes with General Electric Healthcare Services and Novartis, A.G.

Advisors' Opinion:

• [By John Udovich]

  One way or the other, Merrimack Pharmaceuticals Inc (NASDAQ: MACK), Covidien plc (NYSE: COV), NeoGenomics, Inc (NASDAQ: NEO) and�CollabRx Inc (NASDAQ: CLRX) are targeting Barrett's Esophagus�or�esophageal cancer�(the former often leads to the latter) ��a form of cancer that may not be on the top of your list of cancers but is nevertheless on the rise. Approximately 3 million Americans suffer from Barrett's Esophagus, �a condition that�develops as a result of chronic injury from gastroesophageal reflux disease (GERD) where the�normal esophageal lining is replaced with abnormal cells (known as Barrett�� tissue), putting patients at greater risk of developing cancer of the esophagus. And although less than 1% of these patients develop cancer each year, esophageal carcinoma is frequently not detected until later stages, at which point therapy options are limited, extremely invasive, and often ineffective.�This means that�early detection is important�along with�regular surveillance is recommended.�

10 Best Mid Cap Stocks For 2014: Mdu Res Group Inc (MDU)

MDU Resources Group, Inc. operates as a diversified natural resource company in the United States. The company�s Electric segment generates, transmits, and distributes electricity in Montana, North Dakota, South Dakota, and Wyoming. As of December 31, 2012, this segment provided its electric services to approximately 131,000 residential, commercial, industrial, and municipal customers in 177 communities and adjacent rural areas. Its Natural Gas Distribution segment distributes natural gas in Montana, North Dakota, South Dakota, and Wyoming, as well as in Idaho, Minnesota, Oregon, and Washington. This segment served approximately 859,000 residential, commercial, and industrial customers in 334 communities and adjacent rural areas. The company�s Pipeline and Energy Services segment provides natural gas transportation, underground storage, processing, and gathering services, as well as oil gathering through regulated and nonregulated pipeline systems primarily in the Rocky Mountain and northern Great Plains regions of the United States. This segment also provides cathodic protection and other energy-related services. Its Exploration and Production segment engages in the acquisition, exploration, development, and production of oil and natural gas in the Rocky Mountain and Mid-Continent regions of the United States and in and around the Gulf of Mexico. The company�s Construction Materials and Contracting segment mines, aggregates, and markets crushed stone, sand, gravel, and related construction materials, including ready-mixed concrete, cement, asphalt, liquid asphalt, and other value-added products. This segment also provides utility excavation services and inside electrical wiring, cabling, and mechanical services; sells and distributes electrical materials; and manufactures and distributes specialty equipment. MDU Resources Group, Inc. was founded in 1924 and is based in Bismarck, North Dakota.

Advisors' Opinion:

• [By Richard Stavros]

  Created with YCharts

  
  In addition to beating the market since the beginning of the year, diversified energy utilities, such as MDU Resources Group Inc (NYSE: MDU), Dominion Resources Inc (NYSE: D) and Sempra Energy (NYSE: SRE), significantly outperformed pure-play or predominantly all-electric utilities, such as Duke Energy Corp (NYSE: DUK) and Entergy Corp (NYSE: ETR), by as much as several percentage points (See Chart B).
  
  Interestingly, among top performers, there was no dominant strategy for exploiting natural gas demand, as these firms were involved in all aspects of the value chain–from exploration and production to distribution and storage. These companies have not only been benefiting from a natural gas surplus, but also from the pressing need to expand US energy infrastructure to deliver this newfound bounty to businesses and households.
  
  

  Chart B: Diversified Energy Utilities Outperformed Electric-Only Peers

• [By David Dittman]

  Question: I have been a fan of MDU Resources Inc (NYSE: MDU) because of its many operations including oil and gas, materials, construction, and now refining. Long-term thoughts?

10 Best Mid Cap Stocks For 2014: VolitionRX Ltd (VNRX)

VolitionRX Limited, formerly Standard Capital Corporation, incorporated on September 24, 1998, through its wholly owned subsidiary Singapore Volition Pte Limited (Volition), is a life sciences company focused on developing blood-based diagnostic tests. As of October 12, 2011, Volition was developing a range of blood-based epigenetic cancer screening tests, which will be released for research then clinical use in Europe, North America and globally. The tests will enable doctors to screen for the general presence of cancer in the body with a single blood test, and investigate, which cancer is present in many of those cancer positive patients using a panel of tests. On October 6, 2011, the Company announced the closure of the share exchange agreement with the Company. On October 6, 2011, Volition became a wholly owned subsidiary of the Company.

Volition�� HyperGenomics technology will determine specific epigenetic signatures from cancer biopsies. The HyperGenomics range of tests will be used as a second line once cancer has been diagnosed, to determine the specific subtype of disease and to help decide the most appropriate therapy. Volition is developing a non-invasive blood test for endometriosis, based on its Nucleosomics technology.

Advisors' Opinion:

• [By Peter Graham]

  At the end of last week, small cap stocks Senesco Technologies, Inc (OTCBB: SNTI), VolitionRX Ltd (OTCMKTS: VNRX) and Micromem Technologies Inc (OTCBB: MMTIF) were all trending upwards ��ending up 13.65%, 8.73% and 7.61%, respectively, on Friday. However, it�� a new trading week with the last two trading days for the year. So what direction will these three small caps head in for the end of this year and into next year? Here is a quick look to help you decide on a trading or investment strategy:

10 Best Mid Cap Stocks For 2014: Midnight Sun Mining Corp (MMA)

Midnight Sun Mining Corp., formerly Midnight Sun Capital Corp., is an exploration-stage company engaged in the acquisition and exploration of mineral property interests in Canada. On May 12, 2010, the Company completed its Qualifying Transaction and entered into a mineral property option agreement with ATAC Resources Ltd. Under the agreement it agreed to acquire a 100% interest in the Arn mineral properties located in the Whitehorse Mining District, Yukon Territory. The Company announced that it has entered into an agreement dated July 28, 2011, with Logwood Investments Inc., a Namibian company (the Optionor), whereby the Company had acquired the option to earn a 60% interest in certain mineral properties in Namibia. The Klein Aub Copper-Silver Property in Namibia includes the seven optioned properties comprising 3,750 square kilometers of Exclusive Prospecting Licences in Namibia. The northern group of three properties are located 90 kilometers south of the capital city of Windhoek. Advisors' Opinion:

• [By Dividends4Life]

  Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description: 1. Avg. High Yield Price 2. 20-Year DCF Price 3. Avg. P/E Price 4. Graham Number MSFT is trading at a premium to all four valuations above. The stock is trading at a 41.4% discount to its calculated fair value of $68.12. MSFT earned a Star in this section since it is trading at a fair value.Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description: 1. Free Cash Flow Payout 2. Debt To Total Capital 3. Key Metrics 4. Dividend Growth Rate 5. Years of Div. Growth 6. Rolling 4-yr Div. > 15% MSFT earned three Stars in this section for 1.), 2.) and 3.) above. A Star was earned since the Free Cash Flow payout ratio was less than 60% and there were no negative Free Cash Flows over the last 10 years. The stock earned a Star as a result of its most recent Debt to Total Capital being less than 45%. MSFT earned a Star for having an acceptable score in at least two of the four Key Metrics measured. The company has paid a cash dividend to shareholders every year since 2003 and has increased its dividend payments for 12 consecutive years.Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description: 1. NPV MMA Diff. 2. Years to > MMA MSFT earned a Star in this section for its NPV MMA Diff. of the $14,663. This amount is in excess of the $2,300 target I look for in a stock that has increased dividends as long as MSFT has. If MSFT grows its dividend at 17.5% per year, it will take 2 years to

• [By Dividends4Life]

  Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description: 1. Avg. High Yield Price 2. 20-Year DCF Price 3. Avg. P/E Price 4. Graham Number CVX is trading at a discount to only 3.) above. The stock is trading at a 44.9% premium to its calculated fair value of $82.00. CVX did not earn any Stars in this section. Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description: 1. Free Cash Flow Payout 2. Debt To Total Capital 3. Key Metrics 4. Dividend Growth Rate 5. Years of Div. Growth 6. Rolling 4-yr Div. > 15% CVX earned two Stars in this section for 2.) and 3.) above. The stock earned a Star as a result of its most recent Debt to Total Capital being less than 45%. CVX earned a Star for having an acceptable score in at least two of the four Key Metrics measured. The company has paid a cash dividend to shareholders every year since 1912 and has increased its dividend payments for 27 consecutive years. Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description: 1. NPV MMA Diff. 2. Years to > MMA The NPV MMA Diff. of the $256 is below the $800 target I look for in a stock that has increased dividends as long as CVX has. The stock's current yield of 3.37% exceeds the 3.31% estimated 20-year average MMA rate. Memberships and Peers: CVX is a member of the S&P 500, a Dividend Aristocrat, a member of the Broad Dividend Achievers��Index and a Dividend Champion. The company's peer group includes: BP plc (BP) with a 4.7% yield, Exxon Mobil

• [By Dividends4Life]

  Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section (see page 2 of the linked PDF for a detailed description):

10 Best Mid Cap Stocks For 2014: Grana y Montero SAA (GRAM)

Grana y Montero SAA is a Peru-based holding company primarily engaged in the four business areas: Construction and Engineering Industry, Real Estate, Oil Services, and Operation of Public Concessions and Business Support Services. Through its subsidiaries, the Company provides such services as the development and management of real estate properties and leisure facilities; the exploration, production and sale of oil, natural gas and its derivates; the storage and distribution of combustibles; information technology services; engineering consultancy; the operation and maintenance of rails and roads concessions; as well as the execution and management of projects related to the generation of electric power; among others. The Company owns such subsidiaries as GMD SA, Concar SA, Survial SA, Norvial SA and Promotores Asociados de Inmobiliarios SA, among others. Advisors' Opinion:

• [By alicet236]

  Grana y Montero SAA (GRAM) Reached the Five-Year Low of $20.90

  The prices of Grana y Montero SAA (GRAM) shares have declined to close to the five-year low of $20.90, which is 17.3% off the five-year high of $22.14. Grana y Montero SAA is owned by four Gurus we are tracking. Among them, four have added to their positions during the past quarter. Zero reduced their positions. Grana y Montero SAA was established in Peru on August 12, 1996 as a result of the equity spin-off of Inversiones GyM S. Grana Y Montero Saa has a market cap of $2.75 billion; its shares were traded at around $20.90 with a P/E ratio of 24.60 and P/S ratio of 1.24.

10 Best Mid Cap Stocks For 2014: Ophthotech Corp (OPHT)

Ophthotech Corporation, incorporated on January 05, 2007, is a biopharmaceutical company specializing in the development of therapeutics to treat diseases of the eye. The Company�� advanced product candidate is Fovista, which the Company is developing for use in combination with anti-VEGF drugs that represent the current standard of care for the treatment of wet age-related macular degeneration (wet AMD). Wet AMD is a serious disease of the central portion of the retina, known as the macula, which is responsible for detailed central vision and color perception. It is characterized by abnormal new blood vessel formation and growth, referred to as neovascularization, which results in blood vessel leakage, retinal distortion and scar formation. If untreated, the progressive retinal damage results in rapid, irreversible and severe vision loss. Wet AMD is the cause of blindness in patients over the age of 55 in the United States and the European Union.

The anti-VEGF market for the treatment of wet AMD consists predominantly of two drugs that are approved for marketing and primarily prescribed for the treatment of wet AMD, Lucentis and Eylea, and off-label use of the cancer therapy Avastin. The use of anti-VEGF drugs has significantly improved visual outcomes for patients with wet AMD who have been treated with these drugs as compared to untreated patients.

Advisors' Opinion:

• [By Todd Campbell]

  That leads me to Medivation (NASDAQ: MDVN  ) , Ophthotech (NASDAQ: OPHT  ) , and Portola (NASDAQ: PTLA  ) , three companies with important therapies that may very well be destined to become top sellers.

10 Best Mid Cap Stocks For 2014: Hatteras Financial Corp (HTS)

Hatteras Financial Corp., incorporated on September 19, 2007, is an externally managed mortgage real estate investment trust (REIT) that invests primarily in single-family residential mortgage pass-through securities guaranteed or issued by the United States Government agency (such as the Government National Mortgage Association (Ginnie Mae)), or by the United States Government-sponsored entity (such as the Federal National Mortgage Association, (Fannie Mae)), and the Federal Home Loan Mortgage Corporation, (Freddie Mac)). The Company is externally managed and advised by its manager, Atlantic Capital Advisors LLC.

The Company focuses on agency securities consisting of mortgage loans with short durations. The agency securities consist of mortgages that have principal and interest payments guaranteed by Ginnie Mae, Fannie Mae or Freddie Mac. It invests in both fixed-rate and adjustable-rate agency securities. Adjustable rate mortgages (ARMs) are mortgages that have floating interest rates that reset on a specific time schedule, such as monthly, quarterly or annually, based on a specified index, such as the 12-month moving average of the one-year constant maturity United States Treasury rate (CMT) or the London Interbank Offered Rate (LIBOR). The ARMs it generally invests in, sometimes referred to as hybrid ARMS, have interest rates that are fixed for an initial period (typically three, five, seven or 10 years) and then reset annually thereafter to an increment over a pre-determined interest rate index.

Advisors' Opinion:

• [By Amanda Alix]

  A great year for mortgage REITs
  American Capital Agency went public in 2008, a year that saw other mREITs such as Hatteras Financial� (NYSE: HTS  ) , and Armour Residential� (NYSE: ARR  ) enter the territory as well. Groundbreaker Annaly had shown that the carry trade could be lucrative, and the ultra-low short-term interest rate environment created a perfect climate for new companies to enter the playing field.

• [By Amanda Alix]

  When Hatteras Financial (NYSE: HTS  ) declared second-quarter�earnings earlier this week, it was not a pretty sight, as earnings per share missed the mark by $0.04. But that wasn't what set the stage for the carnage that spread throughout the sector: Hatteras reported a huge -- more than 20% -- drop in book value from the first quarter, sending the stock down more than 10% on Wednesday.

• [By Zain Zafar]

  Hatteras Financial (NYSE: HTS  ) �was one of the worst performers during the period despite following a relatively conservative strategy of investing mostly in adjustable-rate mortgage (ARM) mortgage-backed securities, as opposed to fixed-rate 30-year MBSes that can often carry a larger interest rate risk.�